*Upadacitinib

‌Upadacitinib (CAS 1310726-60-3)‌
🌟 ‌ChemicalBook Product Profile‌

📌 ‌Product Overview‌

‌Upadacitinib‌ (C₁₇H₁₉F₃N₆O), a ‌selective JAK1 inhibitor‌, has a molecular weight of ‌380.37 g/mol‌. This ‌white crystalline powder‌ (≥99% purity, HPLC-validated) is widely used for ‌autoimmune disease treatment‌, including rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. It modulates immune responses by targeting JAK-STAT signaling pathways, reducing inflammation with minimal off-target effects. Available in ‌1g/5g/100g‌ sealed aluminum foil packaging, stable for ‌2 years‌ under dark, dry, and low-temperature (-20°C) storage conditions.

‌Google Keywords‌: Upadacitinib CAS 1310726-60-3, JAK1 Inhibitor API Supplier, High-Purity Autoimmune Drug Intermediate, GMP-Certified Pharma Raw Material

✅ ‌Key Advantages‌

🔹 ‌Ultra-High Purity‌

• ≥99% purity (HPLC/NMR validated) | Complies with ‌EP/USP/CP‌ standards.
  🔹 ‌Targeted Selectivity‌

• 74-fold higher selectivity for JAK1 over JAK2/JAK3, minimizing side effects.
  🔹 ‌Stability Assurance‌

• Maintains integrity for ‌2 years‌ with proper storage (-20°C recommended).

🏥 ‌Application Fields‌

• ‌Autoimmune Therapies‌: Core API for oral formulations targeting rheumatoid arthritis and dermatological disorders.

• ‌Clinical Research‌: Key compound in JAK inhibitor development and clinical trials.

• ‌Global API Supply‌: Bulk production for pharmaceutical manufacturers.

📜 ‌Quality Certifications‌

• ‌Testing Methods‌: HPLC, NMR, mass spectrometry, microbial limit testing.

• ‌Certifications‌: ‌GMP‌, ‌ISO 9001‌, and ‌ICH stability guidelines‌ compliance.

📊 ‌Market Trends‌

The ‌global JAK inhibitor market‌ is projected to reach ‌$15.2 billion by 2030‌, growing at ‌6.8% CAGR‌. Upadacitinib holds ‌25% of the JAK1 inhibitor segment‌, with Asia-Pacific (China, India) as the dominant API production and export hub.

📩 ‌Contact us for COA, bulk pricing, and custom synthesis!